(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results